Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65267 | 0.81 | ELANE (0.40) | ELANEPRKCA | |
| SCHEMBL681317 | 0.80 | LMNA (0.32) | ALOX15LMNAHSD17B10ATMBLM | |
| Ammonia Solution, Strong SCHEMBL25421893 | 0.78 | ELANE (0.39) | ELANEPRKCA | |
| SCHEMBL7026388 | 0.78 | ELANE (0.39) | ELANEPRKCA | |
| SCHEMBL28341055 | 0.76 | LMNA (0.30) | LMNAHSD17B10 | |
| SCHEMBL1537712 | 0.75 | ELANE (0.37) | ELANEPRKCA | |
| SCHEMBL15743144 | 0.75 | ELANE (0.37) | ELANEPRKCA | |
| SCHEMBL22362392 | 0.75 | ELANE (0.37) | ELANEPRKCA | |
| SCHEMBL26980854 | 0.74 | ALOX15 (0.39) | ALOX15LMNAHSD17B10 | |
| SCHEMBL4305122 | 0.74 | CHRM2 (0.30) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101611015-A | Indazolyl ester and indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | claimed |
| CN-110709392-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-111757935-A | Bivalent nucleic acid ligand and use thereof | 卡耐基梅隆大学 | 2020-10-09 | — | — | CN | disclosed |
| US-20130004455-A1 | POLY(ORGANOPHOSPHAZENE) COMPOSITION FOR BIOMATERIALS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-01-03 | — | — | US | disclosed |
| US-8313771-B2 | Phosphazene hydrogels with chemical corss-link, preparation method thereof and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-20 | — | — | US | disclosed |
| CN-101611015-B | Indazolyl ester and indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders | ASTRAZENECA AB SE | 2012-09-26 | — | — | CN | disclosed |
| US-20100297155-A1 | PHOSPHAZENE HYDROGELS WITH CHEMICAL CORSS-LINK, PREPARATION METHOD THEREOF AND USE THEREOF | DECA ITALIA S.R.L. (IT) | 2010-11-25 | — | — | US | disclosed |
| CN-101611015-A | Indazolyl ester and indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| EP-1664046-B1 | AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-06-17 | — | — | EP | disclosed |
| CN-101370776-A | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARM INC (US) | 2009-02-18 | — | — | CN | disclosed |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | JIN HAOLUN | 2007-08-09 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1711476-A2 | PYRIMIDYL PHOSPHONATE ANTIVIRAL COMPOUNDS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| EP-1664046-A1 | AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| US-20050282839-A1 | Pyrimidyl phosphonate antiviral compounds and methods of use | GILEAD SCIENCES, INC. | 2005-12-22 | — | — | US | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005070901-A2 | PYRIMIDYL PHOSPHONATE ANTIVIRAL COMPOUNDS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050137199-A1 | Inhibition of HiV integrase compounds | GILEAD SCIENCES, INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2005028478-A1 | AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130004455-A1 | POLY(ORGANOPHOSPHAZENE) COMPOSITION FOR BIOMATERIALS | PHOSPHO1, PGLS, PHYKPL | ELANE 585/4885ALOX15 2046/4885LMNA 2870/4885 |
| US-20050137199-A1 | Inhibition of HiV integrase compounds | CDKL5, CDKL1, CDKL3 | ELANE 1564/4885ALOX15 3781/4885LMNA 680/4885 |
| US-20050282839-A1 | Pyrimidyl phosphonate antiviral compounds and methods of use | TYMP, MTAP, PNP | ELANE 1503/4885ALOX15 3563/4885LMNA 3062/4885 |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | TYMP, PNP, PIKFYVE | ELANE 1963/4885ALOX15 4222/4885LMNA 2126/4885 |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | CDKL5, CDKL1, CDKL3 | ELANE 2446/4885ALOX15 3235/4885LMNA 1002/4885 |
| US-20100297155-A1 | PHOSPHAZENE HYDROGELS WITH CHEMICAL CORSS-LINK, PREPARATION METHOD THEREOF AND USE THEREOF | PRUNE1, PHYKPL, PAPSS1 | ELANE 819/4885ALOX15 3338/4885LMNA 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.